Textbook of Personalized Medicine - Second Edition [2015]

139

Table 4.9 (continued)

Drug Therapeutic area Gene Referenced subgroup
Propafenone Cardiology CYP2D6 CYP2D6 poor metabolizers
Propranolol Cardiology CYP2D6 CYP2D6 poor metabolizers
Protriptyline Psychiatry CYP2D6 CYP2D6 poor metabolizers
Quinidine Cardiology CYP2D6 CYP2D6 poor metabolizers
Quinine Sulfate Infectious diseases G6PD G6PD defi cient
Rabeprazole Gastroenterology CYP2C19 CYP2C19 poor
metabolizers
Rasburicase Oncology G6PD G6PD defi cient
Regorafenib (1) Oncology VEGF VEGFR positive
Regorafenib (2) Oncology KRAS KRAS wt
Regorafenib (3) Oncology EGFR EGFR positive
Rifampin, isoniazid,
and pyrazinamide

Infectious diseases NAT1-2 Slow inactivators

Risperidone Psychiatry CYP2D6 CYP2D6 poor metabolizers
Rituximab Oncology MS4A1 CD20 positive
Rosuvastatin Endocrinology LDLR Homozygous and
Heterozygous familial
hypercholesterolemia
Sodium nitrite Antidotal therapy G6PD G6PD defi cient
Succimer Hematology G6PD G6PD defi cient
Sulfamethoxazole and
trimethoprim

Infectious diseases G6PD G6PD defi cient

Tamoxifen (1) Oncology ESR1, PGR Hormone receptor positive
Tamoxifen (2) Oncology F5 Factor V Leiden carriers
Tamoxifen (3) Oncology F2 Prothrombin mutation
G20210A
Telaprevir Infectious diseases IFNL3 IL28B rs12979860 T allele
carriers
Terbinafi ne Infectious diseases CYP2D6 CYP2D6 poor metabolizers
Tetrabenazine Neurology CYP2D6 CYP2D6 poor metabolizers
Thioguanine Oncology TPMT TPMT poor metabolizer
Thioridazine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Ticagrelor Cardiology CYP2C19 CYP2C19 poor
metabolizers
Tolterodine Urology CYP2D6 CYP2D6 poor metabolizers
Tositumomab Oncology MS4A1 CD20 antigen positive
Tramadol and
Acetaminophen

Rheumatology CYP2D6 CYP2D6 poor metabolizers

Trametinib Oncology BRAF BRAF V600E/K mutation
positive
Trastuzumab Oncology ERBB2 HER2 protein
overexpression positive
Tretinoin Oncology PML/RARA PML/RARα (t(15;17))
gene expression positive
Trimipramine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Valproic Acid (1) Neurology POLG POLG mutation positive
(continued)

Clinical Implications of Pharmacogenetics